10-QPeriod: Q2 FY2017

INTUITIVE SURGICAL INC Quarterly Report for Q2 Ended Jun 30, 2017

Filed July 21, 2017For Securities:ISRG

Summary

Intuitive Surgical Inc. (ISRG) reported strong performance for the second quarter and first half of 2017, demonstrating continued growth in both revenue and procedure volume. Total revenue increased by 13% year-over-year in the second quarter, driven by a 15% increase in recurring revenue, which now represents 71% of total revenue. This growth is largely attributed to a 16% increase in da Vinci procedures performed during the quarter, highlighting the increasing adoption and utilization of the da Vinci Surgical System. The company also saw a 7% increase in systems revenue, with a notable 34% rise in system shipments compared to the prior year period, suggesting expanding market penetration. Financially, the company maintained healthy profitability with gross profit margins around 70% and saw operating income increase by 5%. Despite a significant $2.0 billion accelerated share repurchase program in the first quarter, the company maintained a robust cash position of $3.4 billion in cash, cash equivalents, and investments as of June 30, 2017. Management expressed confidence in their ability to fund future growth through operating cash flows. The company also introduced the new da Vinci X Surgical System in May 2017, which is expected to enhance market reach and affordability.

Financial Highlights

46 data points
Beta

Revenue

$758.80M

69.9% Gross Margin

Net Income

$223.00M

29.4% Net Margin

EPS (Diluted)

$0.65

Total Assets

$5.25B

Cash & Equivalents

$696.50M

Free Cash Flow

$216.50M

Financial Statements
Beta
Revenue$758.80M
Cost of Revenue$228.70M
Gross Profit$530.10M
R&D Expenses$84.60M
SG&A Expenses$185.60M
Operating Expenses$270.20M
Operating Income$259.90M
Net Income$223.00M
EPS (Basic)$0.67
EPS (Diluted)$0.65
Shares Outstanding (Basic)333.00M
Shares Outstanding (Diluted)345.60M

Key Highlights

  • 1Total revenue for Q2 2017 increased by 13% to $756.2 million, driven by strong recurring revenue growth.
  • 2Instrument and accessory revenue (recurring revenue) increased by 17% to $397.8 million, now comprising 71% of total revenue.
  • 3Da Vinci procedures performed grew by 16% in Q2 2017, indicating increasing adoption and utilization of the company's surgical systems.
  • 4System shipments increased by 34% to 166 units in Q2 2017, with the installed base growing by 11% year-over-year to approximately 4,149 systems.
  • 5Gross profit margin remained strong at approximately 70% for both product and total revenue.
  • 6The company maintained a substantial liquidity position with $3.4 billion in cash, cash equivalents, and investments as of June 30, 2017.
  • 7Introduction of the da Vinci X Surgical System in May 2017, offering advanced technology at a more accessible price point.

Frequently Asked Questions

The primary driver of revenue growth was a 15% increase in recurring revenue, which includes revenue from instruments, accessories, and service contracts. This was supported by a 16% increase in the number of da Vinci procedures performed, demonstrating strong utilization of the installed base of surgical systems.

Despite executing a $2.0 billion accelerated share repurchase program in Q1 2017, Intuitive Surgical maintained a healthy cash position of $3.4 billion in cash, cash equivalents, and investments as of June 30, 2017. This was due to strong cash generation from operations and proceeds from employee stock option exercises, which partially offset the repurchase expenditure.

The da Vinci X Surgical System, launched in May 2017, is designed to provide advanced robotic-assisted surgery technology at a lower cost. This is expected to broaden market access for hospitals and surgeons, potentially driving further adoption and revenue growth, especially in markets where price is a significant factor.

The company is involved in several legal proceedings, including product liability lawsuits and shareholder class actions. While the company states that it does not believe the resolution of these matters will have a material adverse effect, significant accruals have been made for product liability claims, and ongoing litigation, particularly patent litigation initiated by Ethicon in July 2017, warrants monitoring.